Biology and treatment of chronic myeloid leukemia

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 3-7

  Jones, Richard J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

BLAST TRANSFORMATION; BONE MARROW TRANSPLANTATION; CELL DEATH; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW;

EID: 0030901273     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00002     Document Type: Review

References (41)

1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
2. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
3. Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
4. bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
5. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990, 87:6649-6653.
6. Bedi A, Zehnbauer BA, Collector MI, Barber JP, Zicha MS, Sharkis SJ, Jones RJ: BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1993, 81:2898-2902.
7. Strife A, Clarkson B: Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin Hematol 1988, 25:1-19.
8. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991, 77:925-929.
9. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994, 83:2038-2044.
10. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83:1179-1187.
11. Laneuville P, Timm M, Hudson AT: Bcr/abl expression in 32D c13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res 1994, 54:1360-1366.
12. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen S, Zon G, Gewirtz AM, Perussia B, Calabretta B: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86:726-736. This paper demonstrates that phosphatidylinositol-3 kinase is a downstream effector of BCR-ABL. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, selectively inhibited the growth of CML cells.
13. De Jong R, Ten Hoeve J, Heisterkamp N, Groffen J: Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 1995, 270:21468-21471. Findings suggest that Cbl, through Crkl, is part of the BCR-ABL signaling pathway.
14. Andoniou CE, Thien CB, Langdon WY: The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Oncogene 1996, 12:1981-1989. Findings suggest that Cbl, through Crkl, is part of the BCR-ABL signaling pathway.
15. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD: The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996, 12:839-846. Cbl and Crkl may link BCR-ABL to the phosphatidylmositol-3 kinase pathway.
16. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995, 92:11746-11750. Findings implicate Jun kinase in the BCR-ABL signaling pathway.
17. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996, 183:811-820. Signal transducers and activators of transcription (STAT) proteins may be downstream of BCR-ABL.
18. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ: Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci U S A 1986, 83:5306-5310.
19. Bhatia R, McGlave PB, Verfaillie CM: Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors: role of MIP-1 alpha. J Clin Invest 1995, 96:931-939.
20. Bhatia R, McCarthy JB, Verfaillie CM: Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996, 87:3883-3891. Findings suggest that CML progenitors are unresponsive to β1-integrin mediated inhibition of proliferation and interferon-α may reverse this. These data may in part explain the mechanism of action of interferon-α.
21. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, De Jong R, Druker B, Heisterkamp N, Chen LB, Groffen J, Griffin JD: Crkl links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995, 270:29145-29150. The focal adhesion protein, paxillin, is shown to be linked to BCR-ABL by Crkl, suggesting that this interaction may in part be responsible for the known adhesion defects in CML cells.
22. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition following DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995, 86:1148-1158. Inhibited apoptosis mediated by BCR-ABL induces resistance to cytotoxic agents, including radiation and most anticancer drugs. BCR-ABL expression did not prevent the induction of DNA damage by the cytotoxic agents or alter the rate of DNA repair. BCR-ABL inhibited the apoptotic deletion of damaged cells, allowing cells time to repair.
23. Fuchs EJ, Bedi A, Jones RJ, Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 1995, 55:463-466.
24. Roger R, Issaad C, Pallardy M, Leglise M, Turhan AG, Bertoglio J, Breard J: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 1996, 87:1113-1122. Although BCR-ABL blocks cytotoxic agent-induced apoptosis, it was unable to inhibit apoptosis induced by natural killer or lymphokine-activated killer cells.
25. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS: Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996, 87:2476-2485.
26. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 1995, 270:22625-22631. This paper contains evidence that BCR-ABL also protects against Fas-mediated apoptosis.
27. Vaux DL, Aguila HL, Weissman IL: Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int Immunol 1992, 4:821-824.
28. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87:3587-3592. Data that a T-cell cytolytic response can be mounted against BCR-ABL-derived peptides, providing a rationale for developing peptide-based vaccines for CML.
29. Bedi A, Griffin CA, Barber JP, Vala MS, Hawkins AL, Sharkis SJ, Zehnbauer BA, Jones RJ: Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res 1994, 54:5535-5538.
30. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996, 87:3069-3081. An up-to-date review of the current status of treatment of CML. The results with standard therapy, including allogeneic BMT and interferon, are summarized. Newer approaches, like donor lymphocyte transfusions and unrelated transplants, and investigational modalities, such as homoharringtonine and autologous BMT. are also reviewed.
31. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR: Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:3987-3996. Data demonstrating that T-cell depletion can be used to decrease graft-versus-host disease in unrelated transplants without a similar decrease in the graft-versus-leukemia effect.
32. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, Van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597. An analysis of 115 patients undergoing unrelated BMT for CML revealed that the best results were obtained in patients in first chronic phase, who were CMV seronegative, and with a donor matched by high-resolution tissue typing techniques.
33. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86:2041-2050. The majority of CML patients who relapse after allogeneic BMT can be reinduced back into remission with donor lymphocyte transfusions. The remissions of patients treated while in chronic phase were durable with 87% still in remission at 3 years.
34. 7/kg) that do not usually produce GVHD.
35. + cells can induce remissions in CML patients who relapse after allogeneic BMT with a low rate of severe graft-versus-host disease.
36. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios M, Andreeff M, Talpaz M: Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995, 86:3322-3326. Homoharringtonine, a plant alkaloid with potent myelosuppressive activity, has shown activity in advanced chronic phase CML, and in patients who have shown resistance to interferon.
37. McGlave PB, De Fabritis P, Deisseroth A: Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994, 343:1486-1488.
38. Marcus RE, Goldman JM: Autografting in chronic granulocytic leukaemia. Clinics Haematol 1986, 15:235-248.
39. Pichert G, Roy D, Gonin R, Alyea EP, Belanger R, Gyger M, Perreault C, Bonny Y, Lerra I, Murray C, Soiffer RJ, Ritz J: Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1995, 13:1704-1713. CML cells are detectable by PCR early after allogeneic BMT in over 80% of patients, suggesting that the preparative regimen alone is unable to eradicate CML cells. Graft-versus-host disease is associated with a decreased ability to detect CML cells by PCR. Thus, the allogeneic graft-versus-leukemia effect is a crucial component of the curative potential of allogeneic BMT in CML.
40. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, DeWald G, Heimfeld S, Miller JS, McGlave PB: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996, 87:4770-4779. Normal progenitors, suitable for use as an autologous marrow graft, can be isolated from most early chronic phase CML patients but not from patients in accelerated phase.
41. + cells from CML patients.